By emphasizing the interplay between systemic vascular health and brain resilience, this Review highlights opportunities to target endothelial dysfunction, neuroinflammation, and metabolic stress as promising strategies for prevention and therapy of vascular dementia.
Abstract
Dementia affects over 55 million individuals worldwide, and its prevalence is projected to triple by 2050. Vascular dementia (VaD) is the second most common cause of cognitive impairment after Alzheimer’s disease (AD), accounting for roughly 20% of all cases. VaD represents a heterogeneous yet mechanistically convergent group of disorders in which vascular injury, blood–brain barrier (BBB) disruption, and neuroinflammation synergistically drive progressive cognitive decline. It arises from diverse etiologies including small-vessel and large-artery disease, chronic cerebral hypoperfusion, and hereditary arteriopathies such as CADASIL, but converges on shared downstream pathways that impair cerebral perfusion, white-matter integrity, and neuronal connectivity. As the global burden of cardiovascular disease rises, vascular contributions to dementia are expected to increase disproportionately, particularly in aging populations. Importantly, epidemiologic evidence consistently links VaD risk to modifiable cardiovascular and metabolic disorders, most notably hypertension, diabetes, and obesity, underscoring its largely preventable nature. Advances in single-cell and spatial transcriptomics, vascularized human brain organoids, and experimental models have revealed how endothelial senescence, oxidative stress, impaired glymphatic clearance, and immune dysregulation disrupt the neurovascular unit. Furthermore, mounting evidence supports bidirectional interactions between vascular injury and amyloid-β and tau pathology, suggesting shared mechanisms between VaD and AD. This Review synthesizes current mechanistic, epidemiologic, and translational insights into vascular contributions to cognitive decline. By emphasizing the interplay between systemic vascular health and brain resilience, we highlight opportunities to target endothelial dysfunction, neuroinflammation, and metabolic stress as promising strategies for prevention and therapy of vascular dementia.
Acute cerebrovascular events once dominated efforts to protect the brain from cardiovascular disease. As stroke prevention and treatment have advanced, attention has broadened to the more continuous vascular processes that contribute to cognitive decline across later life. This review organizes cardiovascular brain inj...
Arash Salardini, Sayena Azarbar· Current Neurology and Neuros...· 0 citations
Cognitive impairment, ranging from mild cognitive impairment to dementia, is increasingly recognized as a potential complication of diabetes. The rising prevalence of diabetes, coupled with an aging population, may lead to a significant increase in the prevalence of cognitive impairment among individuals with diabetes....
N. V. Pizova, A. V. Pizov, I. N. Soloviev· Meditsinskiy sovet = Medical...· 0 citations
An integrated research roadmap for MED is proposed that prioritizes biomarker-enriched cohorts, combination vascular and neurodegenerative therapies, and pragmatic trials, and offers the most plausible strategy to reduce the growing global burden of MED.
Adam de Havenon, Kevin N. Sheth, Carolyn A. Fredericks et al.· Neurotherapeutics· 0 citations
Vascular Cognitive Impairment and Dementia (VCID) is a spectrum of cognitive disorders associated with cerebrovascular disease and is a major cause of cognitive decline and dementia in older adults. This study aimed to review the etiology, risk factors, pathophysiology, diagnostic evaluation, and management of VCID to...
Azka Fadila Latifa, A. As, Muhammad Fatih Ma'ruf et al.· JURNAL BIOLOGI TROPIS· 0 citations
Examining risk factors collectively provides a clearer understanding of brain health vulnerability and supports multidomain prevention strategies that target clustered modifiable risks.
T. Khudair, S. Raeesi, Yashar Zeighami et al.· GeroScience· 0 citations
Alzheimer’s disease (AD) is the leading cause of dementia and a heterogeneous neurodegenerative disorder characterized by amyloid-β (Aβ) and tau pathology, impaired proteostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role...
P. Chmielewski· Cells· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.